


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
16789 (PC25204A)

In Re Application Of: **David Nathan Abraham Fox, et al.**



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/603,369	June 25, 2003	Leslie A. Royds	23389	1614	2797

Title: **NOVEL COMBINATION**

Address to:  
**Commissioner for Patents**  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

- the statement specified in 37 CFR 1.97(e);


**OR**

- the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
 16789 (PC25204A)

In Re Application: David Nathan Abraham Fox, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/603,369	June 25, 2003	Leslie A. Royds	23389	1614	2797

Title: NOVEL COMBINATION

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \$180.00 is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
  - Charge the amount of
  - Credit any overpayment.
  - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_).

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 9, 2005

(Date)


Peter I. Bernstein

Signature of Person Mailing Correspondence

Peter I. Bernstein

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.



Signature

Peter I. Bernstein

Registration No.: 43,497

Scully, Scott, Murphy & Presser  
 400 Garden City Plaza, Suite 300  
 Garden City, New York 11530  
 (516) 742-4343

Dated: June 9, 2005

CC:



**UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant(s):** David Nathan Abraham Fox, et al.      **Examiner:** Leslie A. Royds  
**Serial No:** 10/603,369      **Art Unit:** 1614  
**Filed:** June 25, 2003      **Docket:** 16789 (PC25204A)  
**For:** NOVEL COMBINATION      **Dated:** June 9, 2005

**Confirmation No.:** 2797

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. European Patent Publication No. EP 0 463 756 A1, published January 2, 1992;
2. European Patent Publication No. EP 0 526 004 A1, published February 3, 1993;
3. European Patent Publication No. EP 1 092 718 A1, published April 18, 2001;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: June 9, 2005



Peter I. Bernstein

06/14/2005 HTECKLU1 00000049 10603369  
180.00 DP  
01 FC:1806

H:\work\974\16789\AMEND\16789.ids1.doc

4. European Patent Publication No. 1 092 719 A2, published April 18, 2001;
5. European Patent Publication No. 0 995 750 A1, published April 26 2000;
6. European Patent Publication No. 0 995 751 A2, published April 26, 2000;
7. PCT International Publication No. WO 91/11172, published August 8, 1991;
8. PCT International Publication No. WO 93/06104, published April 1, 1993;
9. PCT International Publication No. WO 93/07149, published April 15, 1993;
10. PCT International Publication No. WO 93/07124, published April 15, 1993;
11. PCT International Publication No. WO 93/12095, published June 24, 1993;
12. PCT International Publication No. WO 94/02518; published February 3, 1994;
13. PCT International Publication No. WO 94/05661, published March 17, 1994;
14. PCT International Publication No. WO 94/00453, published January 6, 1994;
15. PCT International Publication No. WO 95/19978, published July 27, 1995;
16. PCT International Publication No. WO 96/26940, published  
September 6, 1996;
17. PCT International Publication No. WO 98/49166, published  
November 5, 1998;
18. PCT International Publication No. WO 98/55148, published  
December 10, 1998;
19. PCT International Publication No. WO 99/54333, published  
October 28, 1999;
20. PCT International Publication No. WO 99/24433, published May 20, 1999;
21. PCT International Publication No. WO 00/24745, published May 4, 2000;
22. PCT International Publication No. WO 00/27848, published May 18, 2000;
23. PCT International Publication No. WO 01/27113 A2, published  
April 19, 2001;

24. PCT International Publication No. WO 01/27112 A1, published April 19, 2001;
25. PCT International Publication No. WO 01/98304 A1, published December 27, 2001;
26. PCT International Publication No. WO 01/18004 A2, published March 15, 2001;
27. PCT International Publication No. WO 02/00660 A1, published January 3, 2002;
28. PCT International Publication No. WO 02/059126 A1, published August 1, 2002;
29. Fagard R.H., "Epidemiology of Hypertension in the Elderly", *The American Journal of Geriatric Cardiology*, 11(1):23-28 (2002);
30. Brown M.J. et al., "Pathoaeiology, Epidemiology and Diagnosis of Hypertension", *Drugs*, 59 suppl. 2:1-12 (2000);
31. Beevers G. et al., "The Pathophysiology of Hypertension", *BJM*, 322:912-916 (2001);
32. Ballard S.A. et al., "Effects of Sildenafil on the Relaxation of Human Corpus Cavernosum Tissue In Vitro and on the Activities of Cyclic Nucleotide Phosphodiesterase Isozymes", *The Journal of Urology*, 159:2164-2171 (1998);
33. Lipinski C.A. et al., "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings", *Advanced Drug Delivery Reviews*, 23:3-25 (1997);
34. Stopher D. et al., "An Improved Method for the Determination of Distribution Coefficients", *Journal of Pharmacy & Pharmacology*, 42(2):144 (1990);
35. Per Artursson, et al., "Epithelial Transport of Drugs in Cell Culture II: Effect of Extracellular Calcium Concentration on the Paracellular Transport of Drugs of Different Lipophilicities Across Monolayers of Intestinal Epithelial (Caco-2) Cells", *Journal of Pharmaceutical Sciences*, 79(7):595-600 (1990);
36. Obach R.S., "The Prediction of Human Clearance from Hepatic Microsomal Metabolism Data", *Current Opinion in Drug Discovery & Development*, 41(1):36-44 (2001);

37. Shibata Y. et al., "A convenient In Vitro Screening Method For Predicting In Vivo Drug Metabolic Clearance Using Isolated Hepatocytes Suspended in Serum", *Drug Metabolism And Disposition*, 28(12):1518-1523 (2000);
38. Ward K.W. et al., "Development of an In Vivo Preclinical Screen Model to Estimate Absorption and Bioavailability of Xenobiotics", *Drug Metabolism and Disposition*, 28(1):82-88 (2001);
39. Berman J. et al., "Simultaneous Pharmacokinetic Screening of a Mixture of Compounds in the Dog Using API LC/MS/MS Analysis for Increased Throughput", *Journal of Medical Chemistry*, 40(6):827-829 (1997);
40. Han K.S. et al., "Pharmacokinetics of a Chemoprotective Agent, 2-(Allylthio) Pyrazine, After Intravenous and Oral Administration to Rats: Hepatic And Gastric First-Pass Effects", *Drug Metabolism And Disposition*, 27(2):221-226 (1999);
41. Thompson W.J. et al., "Purification and Characterization of High-Affinity Cyclic Adenosine Monophosphate Phosphodiesterase from Dog Kidney", *Biochemistry*, 18(23):5228-5237 (1979);
42. Thompson W.J. et al., "Multiple Cyclic Nucleotide Phosphodiesterase Activities from Rat Brain", *Biochemistry*, 10(2):311-316 (1971);
43. Rotella D.P. et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction", *J. Med. Chem.*, 43:1257-1263 (2000);
44. Pharmaprojects 4516, GlaxoSmithKline; and
45. Pharmaprojects 5051, Abbott.

Applicants are submitting copies of the above-cited references. The relevance of the above-identified references has been described in the specification.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(c), a check in the amount of \$180.00 is enclosed.

Respectfully submitted,



Peter I. Bernstein  
Registration No. 43,497

Scully, Scott, Murphy & Presser  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

PIB/YL:kd

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(REV. 7-80) PATENT AND TRADEMARK OFFICE

JUN 13 2005

JC10

PATENT &amp; TRADEMARK OFFICE

### LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. (Optional)

16789 (PC25204A)

Application Number

10/603,369

Applicant(s)

David Nathan Abraham Fox, et al.

Filing Date

June 25, 2003

Group Art Unit

2797

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
	AC						

**U.S. PATENT APPLICATION PUBLICATIONS**

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
	AC						

**FOREIGN PATENT DOCUMENTS**

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 463 756 A1	1/2/92	Europe				
	0 526 004 A1	2/3/93	Europe				
	1 092 718 A1	4/18/01	Europe				
	1 092 719 A2	4/18/01	Europe				
	0 995 750 A1	4/26/00	Europe				
	0 995 751 A2	4/26/00	Europe				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		Fagard R.H., "Epidemiology of Hypertension in the Elderly", <i>The American Journal of Geriatric Cardiology</i> , 11(1):23-28 (2002)
		Brown M.J. et al., "Pathoaeiology, Epidemiology and Diagnosis of Hypertension", <i>Drugs</i> , 59 suppl. 2:1-12 (2000)

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional)		Application Number			
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		16789 (PC25204A)		10/603,369			
		Applicant(s) David Nathan Abraham Fox, et al.					
		Filing Date June 25, 2003		Group Art Unit 2797			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
<b>FOREIGN PATENT DOCUMENTS</b>							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 91/11172	8/8/91	PCT				
	WO 93/06104	4/1/93	PCT				
	WO 93/07149	4/15/93	PCT				
	WO 93/07124	4/15/93	PCT				
	WO 93/12095	6/24/93	PCT				
	WO 94/02518	2/3/94	PCT				
	WO 94/05661	3/17/94	PCT				
	WO 94/00453	1/6/94	PCT				
<b>OTHER DOCUMENTS</b> ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )							
		Beever G. et al., "The Pathophysiology of Hypertension", <i>BJM</i> , 322:912-916 (2001)					
		Ballard S.A. et al., "Effects of Sildenafil on the Relaxation of Human Corpus Cavernosum Tissue In Vitro and on the Activities of Cyclic Nucleotide Phosphodiesterase Isozymers", <i>The Journal of Urology</i> , 159:2164-2171 (1998)					
EXAMINER			DATE CONSIDERED				
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional) 16789 (PC25204A)		Application Number 10/603,369			
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		Applicant(s) David Nathan Abraham Fox, et al.					
		Filing Date June 25, 2003		Group Art Unit 2797			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
<b>FOREIGN PATENT DOCUMENTS</b>							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 95/19978	7/27/95	PCT				
	WO 96/26940	9/6/96	PCT				
	WO 98/49166	11/5/98	PCT				
	WO 98/55148	12/10/98	PCT				
	WO 99/54333	10/28/99	PCT				
	WO 99/24433	5/20/99	PCT				
	WO 00/24745	5/4/00	PCT				
	WO 00/27848	5/18/00	PCT				
	WO 01/27113 A2	4/19/01	PCT				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
		Lipinski C.A. et al., "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings", <i>Advanced Drug Delivery Reviews</i> , 23:3-25 (1997)					
		Stopher D. et al., "An Improved Method for the Determination of Distribution Coefficients", <i>Journal of Pharmacy &amp; Pharmacology</i> , 42(2):144 (1990)					
EXAMINER			DATE CONSIDERED				
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional) 16789 (PC25204A)		Application Number 10/603,369			
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		Applicant(s) David Nathan Abraham Fox, et al.					
		Filing Date June 25, 2003		Group Art Unit 2797			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
.	AA						
<b>FOREIGN PATENT DOCUMENTS</b>							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/27112 A1	4/19/01	PCT				
	WO 01/98304 A1	12/27/01	PCT				
	WO 01/18004 A2	3/15/01	PCT				
	WO 02/00660 A1	1/3/02	PCT				
	WO 02/059126 A1	8/1/02	PCT				
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
		Per Artursson, et al., "Epithelial Transport of Drugs in Cell Culture II: Effect of Extracellular Calcium Concentration on the Paracellular Transport of Drugs of Different Lipophilicities Across Monolayers of Intestinal Epithelial (Caco-2) Cells", <i>Journal of Pharmaceutical Sciences</i> , 79(7):595-600 (1990)					
		Obach R.S., "The Prediction of Human Clearance from Hepatic Microsomal Metabolism Data", <i>Current Opinion in Drug Discovery &amp; Development</i> , 41(1):36-44 (2001)					
		Shibata Y. et al., "A convenient In Vitro Screening Method For Predicting In Vivo Drug Metabolic Clearance Using Isolated Hepatocytes Suspended in Serum", <i>Drug Metabolism And Disposition</i> , 28(12):1518-1523 (2000)					
EXAMINER			DATE CONSIDERED				
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE			
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		<b>Atty. Docket No. (Optional)</b> 16789 (PC25204A)	
		<b>Application Number</b> 10/603,369	
		<b>Applicant(s)</b> David Nathan Abraham Fox, et al.	
		<b>Filing Date</b> June 25, 2003	<b>Group Art Unit</b> 2797
<b>OTHER DOCUMENTS</b> ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )			
		Ward K.W. et al., "Development of an In Vivo Preclinical Screen Model to Estimate Absorption and Bioavailability of Xenobiotics", <i>Drug Metabolism and Disposition</i> , 28(1):82-88 (2001)	
		Berman J. et al., "Simultaneous Pharmacokinetic Screening of a Mixture of Compounds in the Dog Using API LC/MS/MS Analysis for Increased Throughput", <i>Journal of Medical Chemistry</i> , 40(6):827-829 (1997)	
		Han K.S. et al., "Pharmacokinetics of a Chemoprotective Agent, 2-(Allylthio) Pyrazine, After Intravenous and Oral Administration to Rats: Hepatic And Gastric First-Pass Effects", <i>Drug Metabolism And Disposition</i> , 27(2):221-226 (1999)	
		Thompson W.J. et al., "Purification and Characterization of High-Affinity Cyclic Adenosine Monophosphate Phosphodiesterase from Dog Kidney", <i>Biochemistry</i> , 18(23):5228-5237 (1979)	
		Thompson W.J. et al., "Multiple Cyclic Nucleotide Phosphodiesterase Activities from Rat Brain", <i>Biochemistry</i> , 10(2):311-316 (1971)	
		Rotella D.P. et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction", <i>J. Med. Chem.</i> , 43:1257-1263 (2000)	
		Pharmaprojects 4516, GlaxoSmithKline	
		Pharmaprojects 5051, Abbott	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	
<small>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			